Command Palette

Search for a command to run...

PPLPHARMA

176.56-7.59 (-4.12%)

Quarterly ResultsProfit & LossBalance SheetCash Flow

Key Insights

POSITIVE
  • Net Sales increased significantly in the latest quarter (202503) to ₹2754.07 crore from ₹2204.22 crore, showing strong growth.
  • Operating margin improved dramatically to 7.79% in Q3 2025, a recovery from previous lows, indicating better cost management.
  • Net profit rebounded to ₹153.5 crore in Q3 2025, compared to a minimal profit of ₹3.68 crore in Q2 2024.
NEGATIVE
  • Company experienced a cash flow shortfall with a 10% decrease this year [Dummy Data]
  • Company’s strategic partnerships have yet to generate expected growth. [Dummy Data]
  • Company’s EBITDA shrank at a CAGR of -8% over the past 3 years. [Dummy Data]
Quarterly Results Data
FieldTrendJun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26
Revenue
1,951.142,241.752,204.222,754.071,933.712,043.722,139.872,751.77
Expenses
2,038.162,2002,166.602,539.522,110.442,170.292,246.122,592.63
Operating Profit
-87.0241.7537.62214.55-176.73-126.57-106.25159.14
Other Income
19.5461.1112.1342.0358.4065.6043.2446.06
Interest
106.96107.64103.31103.6886.1582.4289.2482.99
Depreciation
184.55192.22196.81242.76197.28202.84212.74218.38
Profit Before Tax
-45.08120.1266.80272.80-79.02-46.18-93.8643.01
Tax
43.5697.5363.12119.302.6853.0442.3351.83
Net Profit
-88.6422.593.68153.50-81.70-99.22-136.19-8.82
EPS in Rs
-0.670.170.031.16-0.62-0.75-1.03-0.07